

RESPONDER CELLS: RAT SPLEEN CELLS  
STIMULATOR CELLS: HUMAN HEPATOCYTES

SPLEEN(S): SPLEEN CELLS FROM RATS  
TREATED WITH SALINE WHEN THEY WERE  
FETUSES.

HEP: IRRADIATED HUMAN HEPATOCYTES.

SPLEEN(IU): SPLEEN CELLS FROM RATS  
TOLERIZED BY INTRAUTERINE INJECTION OF  
HUMAN HEPATOCYTE LYSATES.

SPLEEN(IU/IS): SPLEEN CELLS FROM RAT  
TOLERIZED BY INTRAUTERINE INJECTION OF  
HUMAN HEPATOCYTE LYSATES FOLLOWED  
BY INTRASPLENIC TRANSPLANTATION OF  
HUMAN HEPATOCYTES AFTER BIRTH.

FIG.1

20230701.032902

1 2 3 4 5

FIG.2

0930781-032802




FIG.3



FIG. 4A



FIG. 4B



FIG. 4C




FIG. 4D

09930781.032802




FIG.5




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D




FIG.7

Time course of human albumin and HBV expression

Anti Human Albumin

Anti Hepatitis B Surface Antigen

1 week



FIG.8A



FIG.8B

6 weeks



FIG.8C




FIG.8D

09030781-032802



2082ED T8/0E66D

14 weeks




FIG. 8E




FIG. 8F

Rat CA2  
Hepatocytes  
Plus HBV

Anti Human Albumin



FIG.9A

Anti Hepatitis B Surface Antigen



FIG.9B

Rat CA3  
Hepatocytes  
alone



FIG.9C




FIG.9D

Rat CA5  
HBV alone




FIG.9E



FIG.9F

Rat CA2  
minus primary Ab



FIG.9G



FIG.9H

2082E0.TB70E660




FIG.10

# RT-PCR Human Albumin RNA





FIG.11A

# RT-PCR HBV RNA



- 1: 1 kbp ladder
- 2: Rat liver RNA
- 3: Human liver RNA
- 4: HepG2.2.15 RNA
- 5: Rat CA2 - Human hepatocytes + HBV,  
1 week post
- 6: Rat CA2 - 6 weeks post
- 7: Rat CA2 - 14 weeks post

FIG.11B




FIG.12

Hepatocytes  
plus HBV

1 week




FIG.13A

Hepatocytes  
plus HBV

6 weeks




FIG.13B

Hepatocytes  
plus HBV

14 weeks





FIG.13C

09930781.032802

Hepatocytes  
plus HBV

1 week


FIG.14A



Hepatocytes  
plus HBV

6 weeks


FIG.14B



Hepatocytes  
plus HBV

14 weeks

FIG.14C



09930781.032802



2092ED-T840E65D




FIG. 15



FIG. 16A



FIG. 16B



FIG. 16C




FIG. 16D




FIG. 16E




FIG. 16F




FIG.17A



FIG.17B




FIG.17C




FIG.17D




FIG.18A




FIG.18B

208220.T8/0E660

09930781.032802




FIG.19A




FIG.19B

208220.18403660




FIG.20




Fig. 21




FIG. 22



Day 1




FIG. 23A



FIG. 23B

X125

X250




FIG. 23C




FIG. 23D

X125

X250

Day 7



FIG. 23E




FIG. 23F

X125

X250

09930781.032802

FIG. 24A



FIG. 24B



FIG. 24C





FIG. 24D



208220-T870E660




FIG. 25

FIG. 26A

Primary human hepatocytes

6 wks 16 wks

Tolerized and  
transplanted


Tolerized but not  
transplanted



FIG. 26B

palb3 plasmid

100 pg 10 pg 1 pg



Arbitrary Units



FIG. 26C

FIG. 27A




FIG. 27C




FIG. 27B

09930781.032802




FIG. 28

**human Albumin**




FIG. 29A

**BrdU**




FIG. 29B

**Tolerized  
with T3  
no trans-  
plantation**



FIG. 29C




FIG. 29D

**Tolerized  
with T3  
and trans-  
plantation**




FIG. 29E




FIG. 29F

**Control  
no T3  
no trans-  
plantation**

09930781.032802

208220.T870E660




FIG. 30



Time Post-HCV Inoculation (weeks)














FIG. 32

Time Post-HCV Inoculation (weeks)

	4	6	8	12	16
Huh7	 +	 +	 +	 +	 +
HepG2					
PHH	 +				
PBS	 +	 -	 -	 -	